Skye Bioscience(SKYE)
SAN DIEGO, CABiotechnology
Focus: Skye Bioscience is a publicly traded cannabinoid-focused biotech developing therapeutics for ophthalmology and metabolic diseases. The company is early-stage with a lean pipeline and limited commercial scale.
Profile data last refreshed 24m ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Skye Bioscience
AI assessmentNot HiringNo open roles listed right now. Follow Skye Bioscience to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Skye Bioscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
SBI-100 Ophthalmic Emulsion, 0.5%
Primary Open Angle GlaucomaClinical Trials (1)
NCT06144918Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure
Phase 2Help build intelligence for Skye Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.